These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22972937)

  • 1. Mixing of the old with the new: nanoparticle-mediated pioglitazone delivery to enhance therapeutic neovascularization.
    Sheng CC; Hong CC
    Arterioscler Thromb Vasc Biol; 2012 Oct; 32(10):2337-8. PubMed ID: 22972937
    [No Abstract]   [Full Text] [Related]  

  • 2. Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia.
    Nagahama R; Matoba T; Nakano K; Kim-Mitsuyama S; Sunagawa K; Egashira K
    Arterioscler Thromb Vasc Biol; 2012 Oct; 32(10):2427-34. PubMed ID: 22879581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation.
    Biscetti F; Straface G; Arena V; Stigliano E; Pecorini G; Rizzo P; De Angelis G; Iuliano L; Ghirlanda G; Flex A
    Cardiovasc Diabetol; 2009 Sep; 8():49. PubMed ID: 19737384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice.
    Huang PH; Sata M; Nishimatsu H; Sumi M; Hirata Y; Nagai R
    Biomed Pharmacother; 2008 Jan; 62(1):46-52. PubMed ID: 17692499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats.
    Zhang M; Gao X; Bai SJ; Ye XM; Zhang J
    Eur Rev Med Pharmacol Sci; 2014; 18(9):1307-14. PubMed ID: 24867508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone, a Peroxisome Proliferator-Activated Receptor x03B3; Agonist, Ameliorates Chronic Kidney Disease by Enhancing Antioxidative Capacity and Attenuating Angiogenesis in the Kidney of a 5/6 Nephrectomized Rat Model.
    Sun L; Yuan Q; Xu T; Yao L; Feng J; Ma J; Wang L; Lu C; Wang D
    Cell Physiol Biochem; 2016; 38(5):1831-40. PubMed ID: 27160248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis.
    Aljada A; O'Connor L; Fu YY; Mousa SA
    Angiogenesis; 2008; 11(4):361-7. PubMed ID: 18810647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells.
    Gensch C; Clever YP; Werner C; Hanhoun M; Böhm M; Laufs U
    Atherosclerosis; 2007 May; 192(1):67-74. PubMed ID: 16876172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of pioglitazone on advanced atherosclerotic lesions.
    Thorp E; Tabas I
    Am J Pathol; 2009 Sep; 175(3):1348. PubMed ID: 19661438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone: more than just an insulin sensitizer.
    Czaja MJ
    Hepatology; 2009 May; 49(5):1427-30. PubMed ID: 19402055
    [No Abstract]   [Full Text] [Related]  

  • 11. PPARgamma agonist pioglitazone reduces [corrected] neuronal cell damage after transient global cerebral ischemia through matrix metalloproteinase inhibition.
    Lee KJ; Jang YH; Lee H; Yoo HS; Lee SR
    Eur J Neurosci; 2008 Jan; 27(2):334-42. PubMed ID: 18215232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of PPAR-γ agonist pioglitazone on renal ischemia/reperfusion injury in rats.
    Reel B; Guzeloglu M; Bagriyanik A; Atmaca S; Aykut K; Albayrak G; Hazan E
    J Surg Res; 2013 Jun; 182(1):176-84. PubMed ID: 22981741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma): a new compound with potent gastroprotective and ulcer healing properties.
    Brzozowski T; Konturek PC; Pajdo R; Kwiecień SN; Konturek S; Targosz A; Burnat G; Cieszkowski J; Pawlik WW; Hahn EG
    Inflammopharmacology; 2005; 13(1-3):317-30. PubMed ID: 16259750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of pioglitazone, one of TZDs, on IGT-patients].
    Kobayashi M
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():462-70. PubMed ID: 15779423
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats.
    Cao Z; Ye P; Long C; Chen K; Li X; Wang H
    Pharmacology; 2007; 79(3):184-92. PubMed ID: 17356310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPAR-gamma: therapeutic target for ischemic stroke.
    Culman J; Zhao Y; Gohlke P; Herdegen T
    Trends Pharmacol Sci; 2007 May; 28(5):244-9. PubMed ID: 17416424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor-γ agonist pioglitazone fails to attenuate renal fibrosis caused by unilateral ureteral obstruction in mice.
    Zhang Y; Wang J; Zhou QD; Zhang CH; Li Q; Huang S; Zhan J; Wang K; Liu YY; Xu G
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):41-47. PubMed ID: 26838738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 20. Rosiglitazone enhances neovascularization in diabetic rat ischemic hindlimb model.
    Khazaei M; Salehi E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Dec; 156(4):312-7. PubMed ID: 23104577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.